Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $18.78 USD
Change Today -0.80 / -4.09%
Volume 695.1K
EPZM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Robert A. Copeland Ph.D.

Chief Scientific Officer and President of Research, Epizyme, Inc.
AgeTotal Calculated CompensationThis person is connected to 10 board members in 1 different organizations across 2 different industries.

See Board Relationships
57$965,745
As of Fiscal Year 2013

Background*

Mr. Robert A. Copeland, also known as Bob, Ph.D., has been the Chief Scientific Officer at Epizyme, Inc. since September 2008 and its President of Research since January 2015 and served as its Executive Vice President since September 2008. Mr. Copeland joined Epizyme in September, 2008. He served as the Vice President of Cancer Biology, Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline. He served scientific staff positions at Merck Research Laboratories, ...

Read Full Background

Corporate Headquarters*

400 Technology Square
Cambridge, Massachusetts 02139

United States

Phone: 617-229-5872
Fax: 617-349-0707

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

Doctorate
Princeton University
Post-Doctoral Training
California Institute of Technology
BS
Seton Hall University

Other Affiliations*

Annual Compensation*

Salary$348,201
Bonus$139,280
Total Annual Compensation$487,481

Stock Options*

All Other Compensation$4,598
Exercisable Options186,123
Unexercisable Options132,051
Total Number of Options318,174

Total Compensation*

Total Annual Cash Compensation$492,079
Total Short Term Compensation$487,481
Other Long Term Compensation$4,598
Total Calculated Compensation$965,745
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EPZM:US $18.78 USD -0.80

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIZYME INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.